Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines
Miguel Ángel Herrera Rojas, CEO, Precision Genomics and Molecular Diagnostics at Nextgene Solutions México, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood, adding:
“From Monterrey to the international guidelines.
In 2013, the group at the Hematology Service of Hospital Universitario ‘Dr. José E. González’ (UANL), led by Dr. David Gómez-Almaguer, presented a then-unconventional idea at ASH: combining eltrombopag with high-dose dexamethasone as first-line therapy for ITP. The full results followed in Blood in 2014.
For years, this approach was questioned and openly criticized. We kept using it, because we saw what it did for our patients.
Thirteen years later, the 2026 ASH Guidelines for Immune Thrombocytopenia now suggest a thrombopoietic agent (or rituximab) plus corticosteroids as initial therapy, a major shift away from steroids alone.
This is more than a personal milestone. It shows what the Hematology Service at HU UANL has been for decades under Dr. Gómez-Almaguer’s leadership: a place that challenges dogma, generates original evidence with limited resources, and changes practice, both in Mexico and internationally.
Original research from Nuevo León is now part of how ITP is treated worldwide. Science from Latin America belongs in the global conversation.
I am deeply grateful to my mentor, Dr. David Gómez-Almaguer, and to all the co-authors who believed in this work.
Most of all, I am grateful to the patients who trusted us.”
Title: Eltrombopag and High-Dose Dexamethasone As First Line Treatment For ITP
Authors: David Gomez-Almaguer, Miguel Angel Herrera-Rojas, Andres Gomez-de Leon, Olga Graciela Cantú-Rodríguez, Cesar H Gutiérrez-Aguirre, Jose Carlos Jaime-Pérez, Luz C. Tarin-Arzaga, Guillermo J. Ruiz-Arguelles, Jesus Hernandez-Reyes

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 20:50Asmaa Beltagy: Efficacy and Safety of Eltrombopag in SLE-Associated Immune Thrombocytopenia
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?
-
Nov 15, 2026, 15:53Nicolas Schommer: The Seed and Soil Hypothesis of NET-Mediated Inflammation
-
Nov 15, 2026, 15:36Giovanni Merlino: Targeting LDL-C to Prevent Recurrent Stroke
-
Nov 15, 2026, 15:33Riitta Lassila: From Helsinki to ISTH 2027 Advancing Thrombosis Research
-
Nov 15, 2026, 15:30Andreas Calatzis: Can Protein C and Plasma Overcome Fibrinolysis Resistance in Sepsis?